Half Yearly Report to 31 March 2015

IXICO announces its unaudited interim results for the six months ended 31 March 2015.

Period Highlights

  • Extension of two clinical trials in Huntington’s Disease, valued at approximately £2.5m over three years
  • VirtualScopics alliance delivering commercial value
  • Partner in the European Prevention of Alzheimer’s dementia Initiative (EPAD)
  • Strengthened capabilities, technology and IP on healthcare data analytics
  • Financial performance underpinned by strong revenue growth of 36% to £1.6m
By |2017-10-11T11:44:08+00:0031 March 2015|Financial|